Calciphylaxis (Calcific Uremic Arteriolopathy): Causes, Symptoms, Diagnosis & Emerging Treatments

Calciphylaxis, also called calcific uremic arteriolopathy, is a rare but serious disorder that most often affects people with end‑stage kidney disease. Calcium‑phosphate crystals deposit in the small arteries and arterioles of the skin and subcutaneous fat, causing painful lesions, ulceration, and a high risk of infection.

Key Symptoms

The condition typically begins as tender, purplish or mottled patches on the lower limbs or other areas with abundant fat (e.g., abdomen, buttocks). Over weeks these patches can progress to necrotic ulcers or firm nodules that heal poorly.

Who Is at Risk?

• Advanced kidney disease or dialysis patients (incidence 0.4%‑4% on dialysis).
• People with abnormal mineral metabolism (elevated calcium, phosphorus, or parathyroid hormone).
• Those receiving certain medications (e.g., vitamin D analogues, warfarin).
• Rarely, individuals with normal kidney function who have severe calcium‑phosphate imbalance or related disorders.

A 2024 study of 333 patients from New Zealand and Australia found a median age of 63 years at diagnosis, with slightly more than half being female.

How Is It Diagnosed?

Physicians suspect calciphylaxis when characteristic painful skin lesions are present. Diagnostic steps include:

• Comprehensive physical examination.
• Skin biopsy to confirm calcium deposition in the vessel walls.
• Laboratory tests to assess calcium, phosphorus, parathyroid hormone, and kidney function.
• Imaging (e.g., bone scan) in selected cases to evaluate the extent of vascular calcification.

Current Management Strategies

There is no definitive cure, so treatment focuses on three pillars: wound care, infection prevention, and correction of mineral abnormalities.

Wound and Skin Care

• Gentle debridement and dressings to promote healing.
• Pain control with appropriate analgesics.

Medications to Modulate Calcium‑Phosphate Balance

• Intravenous sodium thiosulfate – an off‑label chelating agent that may dissolve calcium deposits.
• Cinacalcet (Sensipar) – lowers parathyroid hormone and serum calcium in patients with secondary hyperparathyroidism.
• Non‑calcium phosphorus binders – reduce serum phosphate without raising calcium levels.

Additional Therapeutic Options

• Vitamin K supplementation – a 2019 Massachusetts General Hospital trial investigated its potential benefit; results are pending.
• Parathyroidectomy – surgical removal of overactive parathyroid glands when medical therapy fails.
• Intensified dialysis regimens – more frequent or longer sessions can help control mineral levels.

Prognosis

Calciphylaxis carries a high mortality rate; the 1‑year survival is less than 50 %, largely due to secondary infections and sepsis. Early recognition and aggressive multidisciplinary care improve outcomes, and ongoing research aims to raise survival rates.

What Patients Should Do

If you have end‑stage kidney disease or notice unexplained, painful skin lesions, contact your nephrologist promptly. Discuss strategies to lower calcium‑phosphate load, review your medication list, and ask about enrollment in clinical trials exploring new therapies.